Mitosis dysregulation is common in cancers. This study explored the nuclear expression patterns and prognostic significance of mitotic regulatory proteins, including Aurora kinases, survivin, and p53, in biliary tract cancer (BTC). Archival tumor samples from 161 BTC patients who underwent surgery were tested for the expression of Aurora-A, Aurora-B, survivin, and p53 by immunohistochemistry. The potential endogeneity among the clinicopathologic variables and survival outcome was assessed by a generalized simultaneous equations model. Nuclear overexpression of Aurora-A, Aurora-B, survivin, and p53 was found in 79 (49.1%), 45 (28.0%), 55 (34.2%), and 55 (34.2%) patients, respectively. Intrahepatic cholangiocarcinoma, compared with the other two subtypes, had significantly higher proportions of nuclear overexpression of Aurora-B and survivin (37.8% and 47.3%, respectively). Simultaneous overexpression of Aurora-A and Aurora-B was correlated with that of p53. Overexpression of Aurora-B was also correlated with that of survivin and tumor grade. Our data indicate that simultaneous overexpression of Aurora-A and Aurora-B, suggesting dysregulated mitosis is associated with worse survival in patients with BTC. Independent prognostic factors for poor overall survival included simultaneous overexpression of Aurora-A and Aurora-B (hazard ratio, 1.997; 95% confidence interval, 1.239-3.219; P = 0.0045) and tumor grade (hazard ratio, 2.117; 95% confidence interval, 1.339-3.348; P = 0.0013) assessed by a multivariate analysis stratified by American Joint Committee on Cancer stage and p53 overexpression. Endogeneity testing suggested that nuclear overexpression of p53 and tumor type may influence patient survival through their interactions with Aurora-A/Aurora-B expression and tumor grade. (Cancer Epidemiol Biomarkers Prev 2009;18(2):417 -23) 
Introduction
Biliary tract cancer (BTC) accounts for f10% of the primary cancers occurring in the hepatobiliary system. Owing to a silent course and early dissemination, most BTCs are in the advanced stage when diagnosed, which precludes the possibility of radical resection. Most patients with advanced disease die of hepatic failure or biliary sepsis within 6 to 12 months of diagnosis, indicating poor prognosis and huge unmet medical need for more effective treatments (1) (2) (3) .
Aberrant cell cycle control, a general phenomenon in cancer cells, has been found to be an important avenue for the development of anticancer drugs. In BTC, expression of cell cycle regulatory proteins such as p27 and Mdm2 was found to be dysregulated in the majority of BTC tumor tissues and might have prognostic significance (4) . Clarification of the difference in the expression patterns of these regulatory proteins between cancer cells and normal cells will help us understand the pathogenesis of BTC and identify more novel targets for developing anticancer drugs. For example, the agents targeting cyclin-dependent kinases and their related proteins and mitotic regulatory kinases have entered early-phase clinical trials (5, 6) . These agents may provide new treatment options for this difficult disease.
Aurora kinases are a family of serine/threonine protein kinases that play an essential role in the control of mitosis. Aurora-A and Aurora-B kinases have different localizations during mitosis and regulate distinct functions in mitosis, including spindle assembly, chromosome segregation, and cytokinesis (7, 8) . They are found to be overexpressed in a variety of human cancers (9) . Preclinical and clinical studies have shown promising therapeutic potential of Aurora kinase inhibitors in various cancers (10, 11) .
The functions of Aurora kinases may be affected by the status of the postmitotic checkpoint function, in which the tumor suppressor p53 plays a pivotal role in limiting the endoreduplication after Aurora kinase inhibition (12, 13) . Nuclear overexpression of p53 has been reported in 36% to 86% of patients with BTC and is usually associated with shorter survival (14) (15) (16) (17) . In addition, the activity of Aurora-B can be enhanced by survivin (18) , which is also overexpressed in a variety of cancers. Survivin forms a complex with Aurora-B, inner centromere protein, and borealin and plays an important role in the correct localization of this complex during mitosis (19, 20) . Therefore, delineation of the expression patterns of these mitotic regulatory proteins may help better identify the patients who are most likely to benefit from treatment with Aurora kinase inhibitors.
In this study, we examined the expression patterns of Aurora-A, Aurora-B, survivin, and p53 in the tumor samples of our BTC patients by immunohistochemical staining. We hypothesized that aberrant expression of these mitotic regulatory proteins may help predict overall survival of BTC patients. It is also possible that the expression of some mitotic regulatory proteins may influence survival outcome indirectly, that is, they may interact with other clinicopathologic variables, which in turn predict survival. We tested this hypothesis by statistical modeling.
Materials and Methods
Patients. The study was approved by the Research Ethics Committee of National Taiwan University Hospital. Archival tumor samples were obtained from BTC patients who underwent a surgical attempt as definitive treatment in National Taiwan University Hospital. Patients' demographic characteristics, clinical features, and tumor staging were obtained by review of their medical records. The tumor staging was determined according to the American Joint Committee on Cancer (AJCC) staging criteria (21) . Survival data were obtained by review of medical records and then confirmed by checking the database of Taiwan Cancer Registry and the National Mortality Registration of Taiwan (Department of Health, Executive Yuan).
Immunohistochemical Study. Paraffin-embedded tumor tissue samples were cut in 5 Am sections for immunohistochemical study. These tissue sections were incubated at 65jC for 1 h, deparaffinized in xylene, and then rehydrated. Antigen retrieval was done in a steam bath (100jC, 120 atmospheres) for 40 min. The slides were then treated with 3% H 2 O 2 in methanol for 10 min to inhibit endogenous peroxidase and with goat serum (1:20 dilution) and antibody diluents buffer (DAKO) to block nonspecific binding. The slides were then incubated with the primary antibodies overnight at room temperature. The antibodies used were Aurora-A (Novus), Aurora-B (Novus), survivin (R&D Systems), and p53 (Santa Cruz Biotechnology). The DAKO LSAB2 system was used for signal detection. The slides were first treated with the Biotinylated Link for 20 min and then with the streptavidin-horseradish peroxidase for 20 min. The signals were detected using the DAB+ Substrate Chromogen System (DAKO). Finally, the slides were counterstained with hematoxylin. Staining intensity in the nuclei was graded as mild (+), moderate (++), and strong (+++). Strong staining in the nuclei of >10% tumor cells was considered positive for nuclear overexpression of Aurora-A, Aurora-B, survivin, and p53. Cytoplasmic staining was not considered positive in this study because of frequent positive cytoplasmic staining in the adjacent normal liver or pancreatic tissue.
Statistical Analysis. The correlations between categorical variables were analyzed by m 2 test or Fisher's exact test, whereas the means of continuous variables were compared by two-sample t test or one-way ANOVA. Patients' survival time from the date of operation for BTC to the date of death or last follow-up was recorded. The survival curve was estimated by the Kaplan-Meier method. The difference in hazard rates between groups was compared by the log-rank test.
The prognostic effects of individual demographic, clinical, and pathologic factors, including patient's age, gender, tumor type (cholangiocarcinoma, common bile duct carcinoma, or gallbladder carcinoma), tumor grade (well, moderately, or poorly differentiated), AJCC stage (I/II or III/IV), and nuclear overexpression of Aurora-A, Aurora-B, survivin, and p53, on the hazard rate of overall survival time were jointly assessed by fitting multiple Cox's proportional hazards model. Basic model-fitting techniques for variable selection, goodness-of-fit (GOF) assessment, and regression diagnostics (e.g., residual analysis, detection of influential cases, check for multicollinearity, and test of the proportional hazards assumption) were used to assure the quality of analysis results. In stepwise variable selection procedure, all the univariate significant and nonsignificant covariates were considered and both the significance level for entry and the significance level for stay were set to z0.15. The GOF measure, adjusted generalized R 2 , and Grønnesby-Borgan GOF test (for Cox's proportional hazards model) were examined. If the effects of some risk factors did not satisfy the required proportional hazards assumption, stratified Cox's proportional hazards model would be used.
Our hypothesis that expression of some mitotic regulatory proteins may influence survival outcome indirectly through interaction with other clinicopathologic variables is usually referred to as endogeneity in statistical modeling (22) . To deal with the endogeneity problem in our data set, we specified a three-equation fully recursive generalized simultaneous equations model in our logistic regression analysis. In this model, the covariates of the first equation for survival were set as the response variables of the last two equations and they can then be viewed as the intermediate variables for assessing the direct and indirect effects of the available covariates on the hazard rate of overall survival time (22, 23) .
Statistical analyses were done using the SAS software version 9.1 (SAS Institute). Two-sided P V 0.05 was considered statistically significant.
Results
A total of 161 patients (76 men and 85 women), who underwent surgery for BTC at our institution from 1995 to 2004, were included in this study. Patients with AJCC stage I/II diseases received surgery with curative intent, whereas patients with stage III/IV received palliative surgery only. The demographic, clinical, and pathologic characteristics of these patients with three different tumor types are summarized in Table 1 . The gallbladder carcinoma patients were older and had higher proportions (Table 1) .
Correlations between Nuclear Overexpression of Individual Mitotic Regulatory Proteins and Other Clinicopathologic Features. Nuclear overexpression of Aurora-A was not correlated with nuclear overexpression of the other proteins or any other clinicopathologic features (data not shown). Simultaneous overexpression of Aurora-A and Aurora-B in the same tumor, suggesting dysregulation at multiple steps of mitosis, was correlated with nuclear overexpression of p53 (Supplementary Table S1 ). Overexpression of Aurora-B was also correlated with that of survivin and moderate or poor tumor differentiation (Supplementary Table S2 ). No correlation was found between nuclear overexpression of survivin and p53 (data not shown).
Prognostic Effects of Overexpression of Mitotic
Regulatory Proteins and Other Clinicopathologic Features. The results of univariate analysis are listed in Table 2 . Patients with stage I/II disease who have received curative resection had significantly longer survival time [median, 37.8 months; 95% confidence interval (95% CI), 18.0-57.6 months] than those with stage III/IV disease (median, 9.3 months; 95% CI, 6.3-12.3 months; P < 0.0001). Other factors that predict a poorer survival include poorly differentiated tumors, simultaneous overexpression of Aurora-A and Aurora-B, and overexpression of survivin.
The results of multivariate analysis are summarized in Table 3 . A fitted multiple Cox's proportional hazards model was applied to examine the prognostic significance of the clinicopathologic factors on the hazard rate of overall survival time. Although AJCC stage (I/II versus III/IV) is a strong prognostic factor, it did not satisfy the proportional hazards assumptions in our model. Therefore, it was used in this model as a stratifying variable. Nuclear overexpression of p53 (-versus +) was also used as a stratifying variable for the same reason. As shown in Table 3 , conditioning on the effect of tumor grade (well or moderately differentiated versus poorly differentiated), patients with simultaneous overexpression of Aurora-A and Aurora-B had significantly shorter overall survival time (hazard ratio, 1.997; 95% CI, 1.239-3.219; P = 0.0045) than the other patients. Similarly, conditioning on the effect of Aurora-A/Aurora-B expression [Aurora-A (+)/Aurora-B (+) versus others], patients with poorly differentiated tumors had significantly worse overall survival (estimated hazard ratio, 2.117; 95% CI, 1.339-3.348; P = 0.0013) than those with well or moderately differentiated tumors. The similar magnitude of these two estimated hazard ratios indicates that the prognostic effect of simultaneous overexpression of Aurora-A and Aurora-B was as important as that of tumor grade. The results of our model imply that, given the same status of Aurora-A/ Aurora-B expression and tumor grade, patients with stage III/IV disease or nuclear overexpression of p53 would have worse overall survival.
Although nuclear overexpression of survivin predicted poorer survival in univariate analysis, its prognostic significance was lost in the multivariate analysis model. A stratified analysis was done and the results indicated that overexpression of survivin was associated with poorer survival in patients with stage I/II disease (median overall survival, 11.4 months versus not reached; P = 0.0026), well or moderately differentiated tumors (median overall survival, 12.1 versus 20.6 months; P = 0.038), and intrahepatic cholangiocarcinoma (median overall survival, 12.9 versus 29.2 months; P = 0.016; Supplementary Figure) .
To address the issue of endogeneity, the threeequation fully recursive generalized simultaneous equations model was used to find out clinicopathologic variables that might predict simultaneous expression of Aurora-A and Aurora-B and tumor grade, the two significant predictors of overall survival (Table 4 ). The overexpression of p53 and the tumor types other than common bile duct carcinoma are the two significant predictors of simultaneous overexpression of Aurora-A and Aurora-B. Overexpression of p53 plus the tumor type of intrahepatic cholangiocarcinoma also predicts poor tumor differentiation. The results suggested p53 expression status and tumor types might influence overall survival through their interactions with Aurora-A/Aurora-B expression and tumor differentiation.
Discussion
This study showed the patterns of nuclear overexpression of several key mitotic regulatory proteins, including Aurora-A, Aurora-B, survivin, and p53, and their clinicopathologic correlations in patients with BTC. Simultaneous overexpression of Aurora-A and Aurora-B was shown to be an independent prognostic factor for short overall survival, and nuclear overexpression of p53 also indirectly affected overall survival through interactions with simultaneous expression of Aurora-A and Aurora-B and tumor differentiation. Our data suggested that aberrant mitosis might be important in the pathogenesis of BTC. Nuclear overexpression of either Aurora-A or Aurora-B has been found in a variety of cancers and is usually correlated with tumorigenic characteristics, such as centrosome amplification, aberrant cytokinesis, chromosome instability, and worse outcome (24) (25) (26) . Correlation between expression of Aurora-A and Aurora-B has been found, suggesting the presence of feedback interaction (27) . Although no such correlation was found in the present study, the significantly shorter survival in patients whose tumors expressing both kinases suggests that both kinases are important in the pathogenesis of BTC. Further studies are warranted to explore the therapeutic potential of agents targeting Aurora kinases for the treatment of BTC (28, 29) . Besides, the predictive value of overexpression of Aurora kinases for the efficacy of Aurora kinase inhibitors is a critical issue to be addressed in future clinical trials.
p53 is an important regulator of the mitotic checkpoint in addition to its role in modulation of apoptosis, cell cycle, and DNA damage repair. p53 is activated at the start of mitosis to prevent premature entry into anaphase by regulating several components of this checkpoint, including mitotic arrest deficient 1 and budding uninhibited by benzimidazole 1 (30) (31) (32) (33) . Moreover, p53 status has been found to be a critical determinant of sensitivity of Aurora kinase inhibitors, which are used alone or in combination with either chemotherapy or radiotherapy (34) (35) (36) (37) . Endoreduplication and apoptosis induced by Aurora kinase inhibitors were more potent in p53-deficient cancer cells with compromised postmitotic checkpoint function. In our study, p53 overexpression was found in 34% of patients and was predictive of simultaneous overexpression of Aurora-A and Aurora-B and tumor grade, which in turn predicts poor overall survival. The predictive value of p53 status for efficacy of treatment with Aurora kinase inhibitors, as shown in preclinical models, should be validated in further clinical trials.
BTC is a heterogeneous group of cancers. Different tumor types (intrahepatic cholangiocarcinoma, common bile duct carcinoma, and gallbladder carcinoma) have different pathogenesis and natural history. Our data indicate that the expression patterns of Aurora-B and survivin are different in different tumor types. In addition, results of our statistical modeling indicate that tumor types may interact with other variables, including tumor grade, p53 status, and expression of Aurora-A and Aurora-B, to determine the patients' prognosis in terms of overall survival time. Therefore, to identify novel molecular targets for diagnostic or therapeutic interventions, different tumor types may have to be considered separately.
The correlation of nuclear overexpression among Aurora-B, survivin, and p53 found in our study indicates that complex interactions may exist between the expression and function of mitotic regulatory proteins. Such interactions may bias the estimation of the predictive values of individual variables in conventional regression models (38) . The simultaneous equations model used in this study can be applied to a wider range of response variables in regression modeling than the previously described approaches. Our data implied that the simultaneous overexpression of Aurora-A and Aurora-B and tumor grade can be viewed as Survivin was originally identified as a member of the inhibitor of apoptosis family and its role in the regulation of apoptosis has been extensively studied (39, 40) . However, survivin may also be an important regulator of mitosis. Nuclear expression of survivin in normal cells is cell cycle dependent, which culminates at mitosis (41) . During mitosis, survivin will form a complex with inner centromere protein, borealin, and Aurora-B (42, 43) . Members of this complex are mutually affected in their localization and function during mitosis. A lower incidence (17%) but negative prognostic value of nuclear overexpression of survivin has been reported in a smallscale study of cholangiocarcinoma (44) . Our data suggested that nuclear overexpression of survivin may have prognostic values in some subgroups of BTC patients (stage I/II, intrahepatic cholangiocarcinoma, well or moderately differentiated tumors) and further studies in these subgroups are warranted to confirm its significance as a prognostic biomarker.
There are several limitations in this study. First, the number of patients is small in certain subgroups such as the patients with stage I/II disease and simultaneous overexpression of Aurora-A and Aurora-B (9 patients only). Although our statistical models show the prognostic significance of simultaneous overexpression Aurora-A and Aurora-B independent of tumor stages, larger studies are needed to confirm its prognostic value in specific subgroups of patients. Second, because of the retrospective nature of this study, it is difficult to control certain confounding factors of patient survival, such as types of surgery and other comorbid conditions. Third, immunohistochemical study is semiquantitative in nature and may not reflect the whole spectrum of aberrant regulations of specific factors. For example, the proteinnull phenotype of p53 mutation, which may occur in up to 20% of p53 inactivation in cancers, cannot be detected by immunohistochemical staining. More comprehensive studies are warranted to further delineate the interactions and biological significance between the mitotic regulatory proteins.
In conclusion, our data indicate that simultaneous overexpression of Aurora-A and Aurora-B is associated with worse overall survival of BTC patients. Future studies should focus on confirmation of its prognostic value in specific subgroups of patients and identification of biomarkers to predict response to Aurora kinase inhibitor treatment.
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